Incannex Healthcare (IXHL) Competitors $0.38 -0.01 (-3.77%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (-0.03%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IXHL vs. NRXP, XCUR, RENB, ATHE, RNXT, SNTI, GANX, JSPR, PEPG, and ELYMShould you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include NRx Pharmaceuticals (NRXP), Exicure (XCUR), Renovaro (RENB), Alterity Therapeutics (ATHE), RenovoRx (RNXT), Senti Biosciences (SNTI), Gain Therapeutics (GANX), Jasper Therapeutics (JSPR), PepGen (PEPG), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Incannex Healthcare vs. Its Competitors NRx Pharmaceuticals Exicure Renovaro Alterity Therapeutics RenovoRx Senti Biosciences Gain Therapeutics Jasper Therapeutics PepGen Eliem Therapeutics Incannex Healthcare (NASDAQ:IXHL) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Which has stronger earnings & valuation, IXHL or NRXP? Incannex Healthcare has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncannex Healthcare$10K1,118.63-$18.46M-$1.21-0.31NRx PharmaceuticalsN/AN/A-$25.13M-$2.01-1.44 Is IXHL or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Incannex HealthcareN/A -342.92% -148.64% NRx Pharmaceuticals N/A N/A -355.00% Do insiders and institutionals have more ownership in IXHL or NRXP? 0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 15.5% of Incannex Healthcare shares are held by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer IXHL or NRXP? In the previous week, NRx Pharmaceuticals had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 12 mentions for NRx Pharmaceuticals and 6 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.52 beat NRx Pharmaceuticals' score of 0.04 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, IXHL or NRXP? Incannex Healthcare has a beta of 7.67, suggesting that its share price is 667% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do analysts prefer IXHL or NRXP? NRx Pharmaceuticals has a consensus target price of $28.50, suggesting a potential upside of 886.16%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryNRx Pharmaceuticals beats Incannex Healthcare on 8 of the 15 factors compared between the two stocks. Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXHL vs. The Competition Export to ExcelMetricIncannex HealthcareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.63M$2.75B$5.67B$9.83BDividend YieldN/A1.78%3.79%4.08%P/E Ratio-0.3121.8930.5825.12Price / Sales1,118.63723.29463.91116.12Price / CashN/A177.1637.4059.05Price / Book2.115.079.096.18Net Income-$18.46M$31.61M$3.25B$264.89M7 Day Performance-14.00%5.04%4.76%2.66%1 Month Performance11.79%6.25%6.72%3.05%1 Year Performance-78.77%12.82%30.51%25.05% Incannex Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXHLIncannex Healthcare0.3725 of 5 stars$0.38-3.8%N/A-78.6%$11.63M$10K-0.313Short Interest ↑Gap DownNRXPNRx Pharmaceuticals3.2325 of 5 stars$2.59-3.7%$28.50+1,000.4%+43.5%$44.78MN/A-1.292Short Interest ↓Gap UpXCURExicure2.0357 of 5 stars$7.05-1.1%N/A+1,769.5%$44.56M$500K-1.8550Earnings ReportShort Interest ↓Gap UpHigh Trading VolumeRENBRenovaro1.8963 of 5 stars$0.26+1.2%N/A-65.4%$44.49MN/A-0.3420Short Interest ↓ATHEAlterity Therapeutics3.13 of 5 stars$5.01-1.0%$12.00+139.5%+284.6%$44.44MN/A0.0010RNXTRenovoRx3.1393 of 5 stars$1.21-2.4%$7.25+499.2%+10.7%$44.25M$40K-3.036News CoverageEarnings ReportShort Interest ↓Gap DownSNTISenti Biosciences2.7234 of 5 stars$1.68-1.2%$8.50+406.0%-29.5%$43.81M$2.56M-0.154News CoverageShort Interest ↓Analyst RevisionGANXGain Therapeutics2.3946 of 5 stars$1.44-1.4%$8.20+469.4%+37.5%$43.30M$50K-1.6720News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionJSPRJasper Therapeutics2.9485 of 5 stars$2.88-0.7%$29.75+933.0%-83.1%$43.26MN/A-0.5520News CoverageEarnings ReportAnalyst ForecastPEPGPepGen3.3284 of 5 stars$1.32-3.6%$7.67+480.8%-84.5%$43.19MN/A-0.4230Gap UpELYMEliem TherapeuticsN/A$1.45+3.6%N/A-72.9%$43.14MN/A-2.749 Related Companies and Tools Related Companies NRx Pharmaceuticals Alternatives Exicure Alternatives Renovaro Alternatives Alterity Therapeutics Alternatives RenovoRx Alternatives Senti Biosciences Alternatives Gain Therapeutics Alternatives Jasper Therapeutics Alternatives PepGen Alternatives Eliem Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IXHL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incannex Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access